Results 131 to 140 of about 2,311,361 (335)

Characterization of the Inflammatory Response to Severe COVID-19 Illness

American Journal of Respiratory and Critical Care Medicine, 2020
Rationale: Coronavirus disease (COVID-19) is a global threat to health. Its inflammatory characteristics are incompletely understood. Objectives: To define the cytokine profile of COVID-19 and to identify evidence of immunometabolic alterations in those ...
O. McElvaney, N. McEvoy, O. Mcelvaney, T. Carroll, M. Murphy, Danielle M Dunlea, Orna Ní Choileáin, J. Clarke, E. O'Connor, G. Hogan, Daniel J Ryan, I. Sulaiman, C. Gunaratnam, P. Branagan, M. E. O'Brien, R. Morgan, R. Costello, K. Hurley, S. Walsh, E. de Barra, C. McNally, S. McConkey, F. Boland, S. Galvin, F. Kiernan, J. O'Rourke, R. Dwyer, M. Power, P. Geoghegan, C. Larkin, Ruth A. O’Leary, J. Freeman, A. Gaffney, B. Marsh, G. Curley, N. McElvaney   +35 more
semanticscholar   +1 more source

Elevated Connectivity During Language Processing Is Associated With Cognitive Performance in SeLECTS

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Self‐Limited Epilepsy with Centrotemporal Spikes (SeLECTS) is associated with language impairments despite seizures originating in the motor cortex, suggesting aberrant cross‐network interactions. Here we tested whether functional connectivity in SeLECTS during language tasks predicts language performance.
Wendy Qi, Katharine Lee, Kerry C. Nix, Miguel Menchaca, Xiwei Shé, Lorelei Santa Maria, Wei Wu, Zihuai He, Fiona M. Baumer   +8 more
wiley   +1 more source

Presence of Genetic Variants Among Young Men With Severe COVID-19.

Journal of the American Medical Association (JAMA), 2020
Importance Severe coronavirus disease 2019 (COVID-19) can occur in younger, predominantly male, patients without preexisting medical conditions. Some individuals may have primary immunodeficiencies that predispose to severe infections caused by severe ...
C. I. van der Made, A. Simons, J. Schuurs-Hoeijmakers, G. van den Heuvel, T. Mantere, Simone Kersten, R. V. van Deuren, M. Steehouwer, S. V. van Reijmersdal, M. Jaeger, T. Hofste, G. Astuti, J. Corominas Galbany, Vyne van der Schoot, H. van der Hoeven, W. Hagmolen of ten Have, E. Klijn, Catrien van den Meer, Jeroen Fiddelaers, Q. de Mast, C. Bleeker‐Rovers, L. Joosten, H. Yntema, C. Gilissen, M. Nelen, J. V. D. van der Meer, H. Brunner, M. Netea, F. L. van de Veerdonk, A. Hoischen   +29 more
semanticscholar   +1 more source

Biomarkers for severe COVID-19 [PDF]

EBioMedicine, 2021
Xin Li, Kelvin K.W. To
openaire   +3 more sources

Ofatumumab in Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease: A Comparison With Rituximab

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To evaluate the efficacy and safety of ofatumumab in patients with myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD), and compare it with rituximab. Methods We conducted a single–center, observational study including 22 MOGAD patients treated with ofatumumab and 21 treated with rituximab.
Yuxin Fan, Lei Zhou, Jingzi ZhangBao, Hongmei Tan, Zhouzhou Wang, Chao Quan   +5 more
wiley   +1 more source

Influenza Vaccination Responses in Disabled Stroke Patients: A Single‐Center Prospective Observational Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective This study aimed to investigate the immunological response to influenza vaccination, the incidence and severity of influenza infection, and the side effects of the vaccination in patients with ischemic stroke. Methods This prospective observational study was conducted between 2023 and 2024 at Ramathibodi Hospital.
Achiraya Pakngao, Sureerat Suwatcharangoon, Pintip Ngamjanyapron, Kobporn Boonnak, Thanitta Suangtamai, Porpon Rotjanapan   +5 more
wiley   +1 more source

COVID-19 outcomes in individuals with severe alpha-1 antitrypsin deficiency in Sweden

Scientific Reports
We have previously found using questionnaire/interview data on COVID-19 outcomes, that most subjects with severe alpha-1-antitrypsin deficiency (AATD) exhibit mild COVID-19 infection and those who additionally have COPD are at increased risk of severe ...
Suneela Zaigham, Eeva Piitulainen, Hanan Tanash   +2 more
doaj   +1 more source

Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy. [PDF]

, 2020
The Coronavirus-associated disease, that was first identified in 2019 in China (CoViD-19), is a pandemic caused by a bat-derived beta-coronavirus, named SARS-CoV2.
Ansari, Aftab A, Ceribelli, Angela, De Santis, Maria, Gershwin, M Eric, Motta, Francesca, Ridgway, William M, Selmi, Carlo   +6 more
core  

Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial

European Respiratory Journal, 2020
Introduction There are no determined treatment agents for severe COVID-19. It is suggested that methylprednisolone, as an immunosuppressive treatment, can reduce the inflammation of the respiratory system in COVID-19 patients.
Maryam Edalatifard, M. Akhtari, M. Salehi, Z. Naderi, A. Jamshidi, S. Mostafaei, S. Najafizadeh, E. Farhadi, N. Jalili, M. Esfahani, B. Rahimi, Hossein Kazemzadeh, Maedeh Mahmoodi Aliabadi, T. Ghazanfari, M. Sattarian, Hourvash Ebrahimi Louyeh, S. Raeeskarami, Saeidreza Jamalimoghadamsiahkali, Nasim Khajavirad, M. Mahmoudi, A. Rostamian   +20 more
semanticscholar   +1 more source

CAR T‐Cell Therapy in Neurology: A Scoping Review of Neuro‐Oncology, Autoimmune Diseases & Neurotoxicity

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Chimeric antigen receptor (CAR) T‐cell therapy has been investigated in neurological diseases, encompassing both central nervous system malignancies and autoimmune disorders, thereby extending its application beyond hematological cancers.
Omar Alqaisi, Mohammed Dibas, Patricia Tai, Ala Dibas, Osama Souied, Suhair Al‐Ghabeesh   +5 more
wiley   +1 more source